November 14, 2017

The Abilify MyCite (aripiprazole with sensor) tablets — a collaboration between Otsuka Pharmaceuticals and Proteus Digital Health — send a message from the pill’s sensor to a wearable patch that links to a mobile app.

November 9, 2017
IQVIA also announced that its client solutions would be powered by the IQVIA CORE, which it says allows the company to offer customized solutions for its clients using advanced analytics and extensive industry knowledge.
November 2, 2017
The mantle cell lymphoma treatment is set to be dispensed by a limited group of specialty pharmacies, which include Diplomat Pharmacy and Avella Specialty Pharmacy.
November 1, 2017

The formulation is aimed at meeting the needs of patients with difficulty swallowing. 

October 23, 2017

Bydureon BCise features a continuous-release delivery system that provides consistent levels of the product’s active ingredient, exenatide, to help patients maintain glycemic control, the company said. 

October 23, 2017

The vaccine has shown over 90% efficacy across all age groups in the prevention of shingles, a painful and potentially serious disease that affects one in tnree people in the United States.

October 19, 2017

Yescarta, from Gilead’s recently acquired company Kite, was approved to treat relapsed or refractory large B-cell lymphoma following two or more lines of systemic therapy.

October 18, 2017

As specialty growth looks set to plateau, the drug class continues to see its share of per-capita spending increase, with a decline in spending on traditional medicines creating space for more specialty share.

October 17, 2017

Allergan said that the decision was not the end of the road for their intellectual property protection efforts around Restasis.

October 13, 2017

The organization has named Amgen chairman and CEO Robert Bradway to the chairman-elect position, effective immediately, and named two more industry executives to the board.

October 12, 2017

The Food and Drug Administration on Thursday approved Lyrica CR (pregabalin) controlled-release tablets. 

October 11, 2017

Lupin acquired the company for $150 million, bringing into its drug portfolio Symbiomix’s recently approved single-dose treatment for bacterial vaginosis. 

October 4, 2017

The Food and Drug Administration approved the product in June to treat diabetes.

October 2, 2017

The drug is a formulation featuring the company’s NovoLog insulin aspart developed with the aim of achieving properties that more closely match the natural physiological insulin mealtime response of someone without diabetes.

September 28, 2017

Verzenio works by blocking certain molecules that are involved in cancer cell growth, and it joins two previously approved drugs in this class — palbociclib (Pfizer’s Ibrance) and ribociclib (Novartis’ Kisqali). 

September 25, 2017

The new indication’s approval marks the 10th new indication for Keytruda in three years, Merck said. 

September 19, 2017

Teva has made two separate sales from its global women’s health business in an effort to repay term loan debt. 

September 18, 2017

Solosec is the first approved single-dose oral therapy for bacterial vaginosis. 

September 12, 2017

The legislation aims to make it easier for generics makers to access drug samples of branded products when trying to develop a generic version, many of which are protected by Risk Evaluation and Management Strategies,

September 12, 2017
Recently, patient advocates and regulators have begun acknowledging a need for something to be done about increasing costs of specialty drugs — both for manufacturers and patients. 
 
September 11, 2017

Kåre Schultz Schultz has had a nearly 30-year career in the pharmaceutical and healthcare industries, including a long stint at Novo Nordisk, where he eventually became COO. 

September 8, 2017
The approval means that Admelog has met all requirements for the regulatory agency, pending any patent issues that have not yet been resolved. 
September 5, 2017

Among the potential treatments Gilead will acquire is Kite’s most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), a cancer-fighting therapy expected to be the first to market to treat refractory aggressive non-Hodgkin lymphoma, with a Food and Drug Administration decision date of Nov. 29.

September 5, 2017

The company has named its current global head of drug development and chief medical officer, Dr. Vasant Narasimhan, as CEO, effective Feb. 1, 2018.